Sanofi

RxMx Wins "Best Healthcare Big Data Solution" from MedTech Breakthrough Awards Program

Thursday, May 6, 2021 - 2:15pm

b'NEW YORK, May 6, 2021 /PRNewswire/ -- RxMx Corp., in partnership with Sanofi, a global biopharmaceutical company, has won the "Best Healthcare Big Data Solution" award from the MedTech Breakthrough Awards for a program and series of technology products.\nRxMx is a healthcare company with exceptional technology solutions and longstanding industry experience.

Key Points: 
  • b'NEW YORK, May 6, 2021 /PRNewswire/ -- RxMx Corp., in partnership with Sanofi, a global biopharmaceutical company, has won the "Best Healthcare Big Data Solution" award from the MedTech Breakthrough Awards for a program and series of technology products.\nRxMx is a healthcare company with exceptional technology solutions and longstanding industry experience.
  • The program provides real-time test data to doctors and allows the healthcare team to monitor test data over time.\nAs patients complete their monthly lab work, the RxMx automated monitoring hub relays real-time information about the patient\'s tests to the system.
  • "\n"RxMx has ensured patient safety through the LabWatch program with real-time data while keeping healthcare professionals well informed of the patients\' status," said James Johnson, Managing Director, MedTech Breakthrough.
  • "Congratulations to RxMx again this year this time for our \'Best Healthcare Big Data Solution\' award.

Sporos Launches with $38.1 Million Series A Financing

Thursday, May 6, 2021 - 1:00pm

b'Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities\nLeadership team includes founding chief financial officer Michael Wyzga, formerly of Genzyme\nHOUSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Sporos Bioventures, LLC (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSporos\xe2\x80\x9d), officially launched today with the close of a $38.1 million Series A financing.

Key Points: 
  • b'Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities\nLeadership team includes founding chief financial officer Michael Wyzga, formerly of Genzyme\nHOUSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Sporos Bioventures, LLC (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSporos\xe2\x80\x9d), officially launched today with the close of a $38.1 million Series A financing.
  • The Company, founded by a group of biotech executives, entrepreneurs, academic scholars, and investors, was formed to catalyze the rapid and accurate development of breakthrough therapies that target novel disease mechanisms in cancer and immune diseases.
  • Harnessing its vast network of industry leaders, strategic resources, and operational expertise, Sporos aims to bring new hope to patients in a more efficient and impactful manner.
  • Sporos\xe2\x80\x99 current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.\n'

Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

Thursday, May 6, 2021 - 12:00pm

b'Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization\nPHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of S\xc3\xa9bastien Martel as Senior Vice President of Strategy and Business Development.

Key Points: 
  • b'Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization\nPHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of S\xc3\xa9bastien Martel as Senior Vice President of Strategy and Business Development.
  • Mr. Martel will lead the Company\xe2\x80\x99s corporate strategy and business and corporate development endeavors.
  • Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President, Global Head of Rare Diseases at Sanofi.
  • In this role, Mr. Martel led the global rare disease business through multiple global product launches, commercialization, and disease awareness initiatives, in addition to guiding business development and portfolio strategy.

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Thursday, May 6, 2021 - 6:00am

b'PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ --Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.

Key Points: 
  • b'PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ --Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
  • Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange.
  • "Sanofi\'s collaboration with Stanford University aims to transform how autoimmune disorders and inflammatory conditions are understood and treated.
  • "\nSanofi and Stanford Medicine will create a Joint Steering Committee to fund up to three programs a year.

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Thursday, May 6, 2021 - 6:00am

b'PARIS and Palo Alto, CA \xe2\x80\x93 May 6, 2021 \xe2\x80\x93 Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.

Key Points: 
  • b'PARIS and Palo Alto, CA \xe2\x80\x93 May 6, 2021 \xe2\x80\x93 Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
  • Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange.
  • Together we will explore groundbreaking concepts and obtain deeper insights into underlying inflammatory disease mechanisms,\xe2\x80\x9d said Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi.
  • "Sanofi\xe2\x80\x99s collaboration with Stanford University aims to transform how autoimmune disorders and inflammatory conditions are understood and treated.

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

Wednesday, May 5, 2021 - 12:00pm

The FDA also confirmed that a confirmatory trial would be needed as is required under the accelerated approval pathway.

Key Points: 
  • The FDA also confirmed that a confirmatory trial would be needed as is required under the accelerated approval pathway.
  • The design of the confirmatory trial is intended to be discussed with the FDA prior to a Biologics License Application (BLA) submission.\nDr.
  • The clinical trial will enroll 180 patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) who are na\xc3\xafve to anti-PD1 therapy.
  • Libtayo is being jointly developed by Regeneron and Sanofi.\nIGNYTE is Replimune\xe2\x80\x99s multi-cohort Phase 1/2 trial of RP1 plus Opdivo\xc2\xae.

Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology

Wednesday, May 5, 2021 - 12:00pm

b'WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.

Key Points: 
  • b'WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.
  • Williams joins Kymera with 20 years of drug development experience, including service at Novartis, Sanofi, Millennium, and Curis.
  • She holds a degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Developmental Biology from University College London.
  • In addition, any forward-looking statements represent Kymera Therapeutics\' views only as of today and should not be relied upon as representing its views as of any subsequent date.

Xilio Therapeutics Appoints Christina Rossi to Its Board of Directors

Wednesday, May 5, 2021 - 11:30am

b'Xilio Therapeutics, a biotechnology company developing, tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Christina Rossi, chief commercial officer of Blueprint Medicines, as a member of its board of directors.\n\xe2\x80\x9cI am very pleased to welcome Christy to our board of directors during this exciting phase of growth for our company,\xe2\x80\x9d said Dan Lynch, chairman of the board of directors of Xilio Therapeutics.

Key Points: 
  • b'Xilio Therapeutics, a biotechnology company developing, tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Christina Rossi, chief commercial officer of Blueprint Medicines, as a member of its board of directors.\n\xe2\x80\x9cI am very pleased to welcome Christy to our board of directors during this exciting phase of growth for our company,\xe2\x80\x9d said Dan Lynch, chairman of the board of directors of Xilio Therapeutics.
  • \xe2\x80\x9cChristy is a leader with a proven track record of shaping corporate strategy and leading companies through various stages of development.
  • Rossi joins the Xilio board of directors with 20 years of experience in the pharmaceutical and biotechnology industries.
  • Prior to joining Sanofi Genzyme, Ms. Rossi held various roles at Biogen, Inc, leading brands and a biosimilar-focused venture.

BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021

Tuesday, May 4, 2021 - 12:02pm

The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Key Points: 
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
  • Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
  • BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.\n'

DGAP-News: Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Tuesday, May 4, 2021 - 11:28am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.